Pregabalin, a widely prescribed drug for seizures, has spurred significant interest in the development of analogs with potentially modified pharmacological properties. One notable strategy involves incorporating a 1-beta-carboxylic acid oxide (1-BCO) moiety into the pregabalin scaffold, aiming to alter its pharmacokinetics. This article delves into